Full-Time

Finance Deployment Lead Analyst

Posted on 7/8/2026

Deadline 7/16/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Bengaluru, Karnataka, India

Hybrid

Hybrid work model; on-site days as per schedule.

Category
Business & Strategy (1)
Required Skills
Agile
SAP Products

People at Johnson & Johnson

People at Johnson & Johnson who can refer or advise you

Requirements
  • Minimum of 6+ years professional related experience required
  • MBA (Finance) /CA/ ICWA
  • Ability to comprehend SAP design documentation and test scripts
  • Knowledge and experience working with SAP S/4 HANA Finance is a must.
  • Solid understanding of Overall Finance Process is required.
  • Strong analytic skills and ability to balance big picture with attention to detail
  • Hard-working to develop expertise in sophisticated financial topics
  • Agile outlook
  • Good communication skills and ability to clearly articulate complex issues
  • Great teammate and collaborative working style
Responsibilities
  • Support the Finance workstream through the deployment phases of all Transcend releases
  • Assist Data Migration, Business Simulation Testing (BST), User Acceptance Testing (UAT), Business Adoption, Cutover, and Hypercare
  • Partner with Business Process Owners (BPO) and Global Template Owners (GPO) on global template development and deployment
  • Identify and analyse deployment risks and mitigation activities
  • Identify workstream interdependencies with outside programs (Signifi Transact, MT Transcend, others)
  • Provide Credo based leadership to foster an environment of inclusiveness and continued career and personal development
  • Prepare the data conversion and validation as part of the integration
  • Support data mapping validation
  • Assist validation activities and enforce to timelines according to deployment map
  • Ensure high quality data is delivered in line with Common Information Model standards
  • Support BST and UAT cycles for each release
  • Partner with IT, Global Template Owners, and Business Process Owner teams to resolve test defects
  • Review and analyse testing results in line with compliance standards
  • Partner with Business Adoption Leads, Business Process Owner Team, Base Business Stakeholders to deploy end to end organizational change strategies
  • Support post-go live hyper care period to ensure end users can perform all essential functions in the period following go live
  • Ensure consistency to J&J change management framework
Desired Qualifications
  • Experience as Lead Analyst for a large manufacturing site
  • Experience leading testing cycles – BST, UAT, data validation
  • Knowledge of digital tools (PowerQuery, PowerBI)
  • Experience with working in global / virtual environments
  • Experience using Jira project tool
  • Experience in Central Finance
  • Budgeting, Budget Management, Coaching, Communication, Expense Controls, Financial Analysis, Financial Competence, Financial Disclosures, Financial Forecasting, Financial Modeling, Financial Reports, Financial Risk Management (FRM), Financial Statement Analysis, Leverages Information, Problem Solving, Relationship Building, Technical Credibility, Vendor Management

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

People at Johnson & Johnson

People at Johnson & Johnson who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • MedTech division targets mid-single-digit growth via cardiovascular acquisitions like Shockwave and Abiomed.
  • Oncology portfolio strengthened by MonumenTAL-3 data for TALVEY in relapsed/refractory multiple myeloma.
  • FDA approval of dual-energy cardiac ablation platform enables phased US commercial rollout starting summer 2026.

What critics are saying

  • Talc litigation includes a $1.5 billion verdict and 68,000+ pending cases with no global settlement by 2026.
  • Bankruptcy shield dismissed in 2025, exposing J&J to direct liability and massive payouts within 6–12 months.
  • China sales face headwinds from volume-based procurement, with pressures persisting through second half of 2026.

What makes Johnson & Johnson unique

  • J&J operates across medicine, medical devices, and consumer health, unlike pure biopharma peers.
  • It leads in bispecific oncology with TALVEY and advances next-generation tri-specific antibodies.
  • J&J separates orthopaedics to focus on high-growth medicine and MedTech segments over 24 months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-1%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.